KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Long-Term Investments: 2020-2025

Historic Long-Term Investments for AbCellera Biologics (ABCL) over the last 5 years, with Sep 2025 value amounting to $93.3 million.

  • AbCellera Biologics' Long-Term Investments rose 10.96% to $93.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $93.3 million, marking a year-over-year increase of 10.96%. This contributed to the annual value of $82.3 million for FY2024, which is 24.81% up from last year.
  • AbCellera Biologics' Long-Term Investments amounted to $93.3 million in Q3 2025, which was up 3.24% from $90.4 million recorded in Q2 2025.
  • In the past 5 years, AbCellera Biologics' Long-Term Investments ranged from a high of $93.3 million in Q3 2025 and a low of $32.2 million during Q1 2021.
  • In the last 3 years, AbCellera Biologics' Long-Term Investments had a median value of $76.1 million in 2024 and averaged $75.0 million.
  • As far as peak fluctuations go, AbCellera Biologics' Long-Term Investments surged by 161.41% in 2021, and later declined by 10.68% in 2023.
  • Quarterly analysis of 5 years shows AbCellera Biologics' Long-Term Investments stood at $50.3 million in 2021, then skyrocketed by 44.14% to $72.5 million in 2022, then fell by 9.08% to $65.9 million in 2023, then increased by 24.81% to $82.3 million in 2024, then climbed by 10.96% to $93.3 million in 2025.
  • Its last three reported values are $93.3 million in Q3 2025, $90.4 million for Q2 2025, and $81.6 million during Q1 2025.